The Price of a Trial That Fails

Transcript

When a clinical trial collapses, the bill goes far beyond the trial budget. Sponsors may lose spending on staff, research sites, screening, procedures, data collection, and regulatory work. Delays can add even more costs, while years of earlier investment and potential future revenue may also disappear. Some estimates put the cost of a failed Phase Three trial above one hundred million dollars, though estimates vary widely. The ethical cost is just as serious. Participants may face risks, inconvenience, or interrupted care without receiving a personal benefit or helping produce reliable medical knowledge. Abrupt closures can damage trust, especially if results are not reported. And there is an opportunity cost. Patients, researchers, funding, and scarce research sites tied up in an uninformative study cannot support better questions elsewhere. The result can be delayed medical progress and slower access to effective treatments. Early stopping can be responsible when safety or clear evidence demands it, but even then, the evidence should be preserved and shared.